{"id":"tislelizumab-platinum-based-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab is a humanized monoclonal antibody that binds to programmed death receptor-1 (PD-1), preventing interaction with its ligands (PD-L1/PD-L2) and thereby releasing the brake on T-cell-mediated anti-tumor immunity. Platinum-based chemotherapy induces DNA damage and cell death while potentially increasing tumor immunogenicity. The combination leverages both direct cytotoxic chemotherapy and immune checkpoint inhibition for synergistic anti-tumor activity.","oneSentence":"Tislelizumab blocks PD-1 on T cells to restore anti-tumor immunity, combined with platinum chemotherapy to enhance cytotoxic effects against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:57.884Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy"},{"name":"Squamous cell carcinoma of the head and neck in combination with platinum-based chemotherapy"}]},"trialDetails":[{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07120282","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-28","conditions":"Lung Cancer (NSCLC)","enrollment":108},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT05502250","phase":"PHASE2","title":"Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2023-07-14","conditions":"Hodgkin Lymphoma","enrollment":75},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT07416474","phase":"PHASE3","title":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":574},{"nctId":"NCT05577702","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-03-08","conditions":"Non Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT07388758","phase":"PHASE2","title":"Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":37},{"nctId":"NCT07385703","phase":"PHASE3","title":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03","conditions":"Adenocarcinoma","enrollment":752},{"nctId":"NCT07383116","phase":"PHASE3","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-01-15","conditions":"Non Squamous Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT07131319","phase":"PHASE2, PHASE3","title":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-04-21","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07373990","phase":"PHASE3","title":"Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-15","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":418},{"nctId":"NCT06764355","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-07-23","conditions":"ESCC, Total Neoadjuvant Treatment, Pathological Complete Response","enrollment":50},{"nctId":"NCT03967977","phase":"PHASE3","title":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2019-05-29","conditions":"Urothelial Carcinoma","enrollment":420},{"nctId":"NCT07353294","phase":"PHASE1","title":"Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Bladder Urothelial Carcinoma, Lymph Node Metastasis","enrollment":12},{"nctId":"NCT07346807","phase":"PHASE2","title":"Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-01","conditions":"Tongue Squamous Cell Carcinoma","enrollment":69},{"nctId":"NCT07330037","phase":"PHASE2","title":"TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC","enrollment":41},{"nctId":"NCT07320105","phase":"PHASE4","title":"Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-15","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT06877299","phase":"PHASE2","title":"Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-04","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT04974047","phase":"PHASE2","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-17","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT05516914","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2022-09-01","conditions":"Malignant Tumors","enrollment":490},{"nctId":"NCT07170995","phase":"PHASE3","title":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-10-22","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":460},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT07172412","phase":"PHASE2","title":"Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11","conditions":"Extensive Stage Lung Small Cell Cancer","enrollment":165},{"nctId":"NCT07198217","phase":"PHASE2","title":"Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient","status":"RECRUITING","sponsor":"Zibo Municipal Hospital","startDate":"2021-05-25","conditions":"NSCLC, Tislelizumab, Chemotherapy","enrollment":20},{"nctId":"NCT06838208","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-02-25","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":56},{"nctId":"NCT05014815","phase":"PHASE2","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-11-16","conditions":"Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV","enrollment":272},{"nctId":"NCT06893380","phase":"","title":"Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"CHA University","startDate":"2024-10-01","conditions":"Locally Advanced Biliary Tract Cancers, Metastatic Biliary Tract Cancers","enrollment":61},{"nctId":"NCT05758389","phase":"PHASE2","title":"Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-04-01","conditions":"Head and Neck Tumors","enrollment":29},{"nctId":"NCT07145931","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy","enrollment":24},{"nctId":"NCT05880082","phase":"PHASE2","title":"PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-01-13","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07119996","phase":"PHASE1","title":"Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":12},{"nctId":"NCT06896422","phase":"PHASE1","title":"Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-06-01","conditions":"Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody","enrollment":80},{"nctId":"NCT07109401","phase":"PHASE2","title":"Perioperative Immunotherapy for Resectable Limited-Stage SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT04570410","phase":"PHASE2","title":"Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-12-01","conditions":"Bladder Urothelial Carcinoma","enrollment":30},{"nctId":"NCT07099547","phase":"PHASE2","title":"Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-09","conditions":"Biliary Tract Carcinoma","enrollment":60},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT07085182","phase":"PHASE2","title":"Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study","status":"RECRUITING","sponsor":"Zibo Municipal Hospital","startDate":"2024-01-13","conditions":"NSCLC, Tislelizumab, Chemotherapy","enrollment":20},{"nctId":"NCT07080437","phase":"","title":"An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Three Gorges Hospital of Chongqing University","startDate":"2021-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":40},{"nctId":"NCT07046221","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Esophagus Cancer","enrollment":60},{"nctId":"NCT04921358","phase":"PHASE3","title":"Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-07-27","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":377},{"nctId":"NCT06977828","phase":"PHASE2","title":"A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-07-20","conditions":"NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy","enrollment":40},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT05319574","phase":"PHASE2","title":"SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-04-24","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":46},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT06446726","phase":"PHASE2","title":"Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-06-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06969612","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":21},{"nctId":"NCT04821765","phase":"PHASE2","title":"Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-10-01","conditions":"Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease","enrollment":35},{"nctId":"NCT06598527","phase":"PHASE3","title":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study","status":"RECRUITING","sponsor":"Yang Hong","startDate":"2024-10-15","conditions":"Lung Cancer (NSCLC)","enrollment":360},{"nctId":"NCT06977074","phase":"PHASE2","title":"PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-10","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":83},{"nctId":"NCT05516589","phase":"PHASE2","title":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-09-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06659042","phase":"PHASE2","title":"Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-11-20","conditions":"Lung Cancer, Non-Small Cell","enrollment":32},{"nctId":"NCT03957590","phase":"PHASE3","title":"A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-06-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":370},{"nctId":"NCT06951841","phase":"PHASE4","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-04-30","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT06939127","phase":"PHASE2","title":"Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":38},{"nctId":"NCT06916494","phase":"PHASE1","title":"Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-05-01","conditions":"Muscle Invasive Bladder Cancer","enrollment":10},{"nctId":"NCT06908733","phase":"PHASE2","title":"Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer (Stage III)","enrollment":30},{"nctId":"NCT06903273","phase":"PHASE2","title":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Biliary Tract Cancer (BTC)","enrollment":35},{"nctId":"NCT04005716","phase":"PHASE3","title":"Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-07-22","conditions":"Small Cell Lung Cancer","enrollment":457},{"nctId":"NCT06364904","phase":"PHASE3","title":"A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10","conditions":"Bladder Cancer","enrollment":210},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT05532059","phase":"PHASE2","title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-31","conditions":"Advanced Cholangiocarcinoma","enrollment":100},{"nctId":"NCT05823311","phase":"PHASE3","title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-01","conditions":"Advanced Cholangiocarcinoma","enrollment":80},{"nctId":"NCT03663205","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-07-23","conditions":"Non-Small Cell Lung Cancer","enrollment":334},{"nctId":"NCT03924986","phase":"PHASE3","title":"Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-03-27","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer","enrollment":263},{"nctId":"NCT06781112","phase":"PHASE2","title":"A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Weiwei Zhang","startDate":"2025-01-20","conditions":"TPF, Immunotherapy, Nasopharyngeal Carcinoma","enrollment":35},{"nctId":"NCT06403111","phase":"PHASE2","title":"FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC","status":"RECRUITING","sponsor":"Changzhou No.2 People's Hospital","startDate":"2024-06-01","conditions":"Non-small Cell Lung Cancer","enrollment":62},{"nctId":"NCT06704620","phase":"PHASE3","title":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12","conditions":"Advanced and Metastatic NSCLC","enrollment":430},{"nctId":"NCT06728618","phase":"PHASE2","title":"Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-12","conditions":"Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma","enrollment":28},{"nctId":"NCT06725498","phase":"PHASE2","title":"Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06696742","phase":"PHASE2","title":"PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-02-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":60},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06690476","phase":"EARLY_PHASE1","title":"Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-10-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":74},{"nctId":"NCT05919030","phase":"PHASE3","title":"A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":155},{"nctId":"NCT03469557","phase":"PHASE2","title":"BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-07-18","conditions":"Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma","enrollment":30},{"nctId":"NCT03432598","phase":"PHASE2","title":"Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-08-24","conditions":"Locally Advanced Lung Cancer; Metastatic Lung Cancer","enrollment":54},{"nctId":"NCT06614231","phase":"PHASE2","title":"Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-20","conditions":"NSCLC, Stage IIIA, NSCLC (non-small Cell Lung Cancer)","enrollment":48},{"nctId":"NCT06536868","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC","status":"RECRUITING","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2024-08-01","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":40},{"nctId":"NCT05531123","phase":"PHASE2","title":"Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-09-10","conditions":"Bladder Cancer","enrollment":30},{"nctId":"NCT06475755","phase":"PHASE2","title":"Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-06-30","conditions":"Non-Small Cell Lung Cancer, Anti Angiogenesis","enrollment":178},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06387056","phase":"PHASE2","title":"Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-04-01","conditions":"Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer","enrollment":40},{"nctId":"NCT06375109","phase":"PHASE2","title":"PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital, Capital Medical University","startDate":"2024-04-16","conditions":"Limited-stage Small-cell Lung Cancer","enrollment":60},{"nctId":"NCT06357598","phase":"PHASE4","title":"Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2024-01-18","conditions":"Non-small-cell Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT06331845","phase":"PHASE2","title":"Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-05-01","conditions":"Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy","enrollment":39},{"nctId":"NCT06235918","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Xiang Lu","startDate":"2023-01-01","conditions":"Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma","enrollment":30},{"nctId":"NCT05611879","phase":"PHASE2","title":"Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-03-12","conditions":"NSCLC, Stage III","enrollment":30},{"nctId":"NCT05588219","phase":"PHASE2","title":"Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Yong Zhang,MD","startDate":"2022-12-01","conditions":"Uterine Cervical Neoplasms","enrollment":30},{"nctId":"NCT06136910","phase":"PHASE1, PHASE2","title":"Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-05-09","conditions":"Untreated Advanced Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06130007","phase":"PHASE2","title":"A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.","status":"UNKNOWN","sponsor":"Xuekui Liu","startDate":"2023-11-25","conditions":"Oral Squamous Cell Carcinoma","enrollment":48},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tislelizumab + platinum-based chemotherapy","genericName":"Tislelizumab + platinum-based chemotherapy","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab blocks PD-1 on T cells to restore anti-tumor immunity, combined with platinum chemotherapy to enhance cytotoxic effects against cancer cells. Used for Non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy, Squamous cell carcinoma of the head and neck in combination with platinum-based chemotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}